The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia.
BACKGROUND
There are few data on the natural course of Helicobacter pylori-related atrophic gastritis.


OBJECTIVE
To investigate the effect of H. pylori eradication on advanced atrophic gastritis in the corpus.


METHODS
Twenty-two elderly men with H. pylori infection and moderate or severe atrophic corpus gastritis formed the study population. These men were under endoscopic surveillance because of the presence of indefinite or definite dysplastic gastric lesions in addition to atrophic corpus gastritis. The men were gastroscopically and bioptically examined four times before they received H. pylori eradication therapy (mean follow-up time, 7.5 years), and once again 2.5 years after eradication therapy. Serum levels of pepsinogen I and H. pylori antibodies were analysed at baseline, immediately before and 2.5 years after eradication therapy.


RESULTS
During the 7.5-year period prior to eradication therapy, no significant changes were observed in the mean atrophy and intestinal metaplasia scores or in the mean serum level of pepsinogen I. However, a significant improvement occurred in the mean histological scores of inflammation (from 2.2 to 0.5), atrophy (from 2.2 to 1.2) and intestinal metaplasia (from 1.6 to 1.1) in the corpus mucosa after H. pylori eradication. In addition, the mean serum level of pepsinogen I increased from 16.3 to 25.7 microg/L (P=0.0071, Wilcoxon signed rank test) after eradication therapy.


CONCLUSIONS
The results suggest that advanced atrophic corpus gastritis (and intestinal metaplasia) improves and may even heal after the eradication of H. pylori.
Kokkola
A
A
Second Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland. arto.kokkola@hus.fi
Sipponen
P
P
Rautelin
H
H
Härkönen
M
M
Kosunen
T U
TU
Haapiainen
R
R
Puolakkainen
P
P
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004338:Drug Combinations; D005757:Gastritis, Atrophic / Q000150:complications / Q000188:drug therapy / Q000382:microbiology* / Q000503:physiopathology*; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D016480:Helicobacter pylori / Q000276:immunology / Q000502:physiology*; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012698:Serologic Tests
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D064747:Lansoprazole; D008795:Metronidazole; D000658:Amoxicillin; D009853:Omeprazole